Home > Back to Publisher > Report Information

Metabolic Diseases Pipeline Analysis:Focus on Dyslipidemia, Diabetes, and Obesity

Decision Resources
November 5, 2005
83 Pages - SKU: DECR1255338

Abstract Table of Contents Related Reports

Metabolic diseases affect millions of people worldwide. Thousands of metabolic diseases have been identified in humans, yet just a handful of these diseases account for the vast majority of the morbidity and mortality. The World Health Organization (WHO) estimates that type 2 diabetes affects 135 million people worldwide and that 300 million people meet the criteria for obesity. Dyslipidemia is another major metabolic disorder, affecting approximately 300 million people in the United States, Japan, and Western Europe.

Because these three disorders--type 2 diabetes, obesity, and dyslipidemia--are highly prevalent and lead to significant morbidity and mortality, they are the main focus of this report. We also discuss several metabolic disorders that are less severe but account for significant morbidity. These disorders include ""metabolic syndrome"" (which comprises several conditions), polycystic ovarian syndrome (PCOS), and non-alcoholic steatohepatitis (NASH). (We do not discuss hypertension, a common feature of metabolic syndrome, in this report because it is multifactorial in origin and not generally considered a metabolic disorder.)

In this report, we review the etiology and biological features of the aforementioned disorders and discuss the major marketed and emerging classes of drugs used in treatment. (At present, no drugs are commercially available for the treatment of NASH or PCOS.) Following this discussion, we profile companies that either have launched drugs for major metabolic diseases or have drugs in late-stage clinical development. (We do not profile manufacturers of generic drugs targeting these diseases, although we discuss their drugs when relevant.) We conclude with a discussion of the commercial outlook for pharmacological therapies targeting metabolic disorders.

Please note: the PDF e-mail from publisher version of this report is for a global site license.

Executive Summary: Which companies are the major players in the metabolic disease market?; Which companies are the emerging players developing promising treatments for metabolic diseases?; What is the commercial outlook for the metabolic disease market?
Chapter 1. Background of a Worldwide Epidemic
Chapter 2. Overview of Metabolic Diseases: Type 2 Diabetes; Obesity; Dyslipidemia; Metabolic Syndrome; Non-Alcoholic Steatohepatitis; Polycystic Ovarian Syndrome
Chapter 3. Current and Emerging Treatments for Metabolic: Diseases; Drugs Targeting Type 2 Diabetes; Insulin; Inhaled Insulin; Oral Insulin; Sulfonylurea Drugs; Meglitinides; Biguanides; Alpha-Glucosidase Inhibitors; PPAR Agonists (Thiazolidinediones); Amylin Analogues; Incretin Mimetics; DPP-IV Inhibitors; SGLT2 Inhibitors; 11-Beta-HSD Type 1 Inhibitors; Beta-3 Adrenergic Agonists; Drugs Targeting Obesity; Noradrenergic Anorectic Agents; Serotonin-Norepinephrine Reuptake Inhibitors; Lipase Inhibitors; Melanin-Concentrating Hormone Receptor Antagonists; Cannabinoid Antagonists; Neuropeptide Y Agonists; Decision Resources, Inc. i DR Pipeline Reports Drugs Targeting Dyslipidemia; Statins (HMG-CoA Reductase Inhibitors); Fibric Acids; Bile Acid Sequestrants; Nicotinic Acid; Cholesterol Absorption Inhibitors; Cholesteryl Ester Transferase Protein Inhibitors; Squalene Synthase Inhibitors; Microsomal Triglyceride Transfer Protein Inhibitors; Acyl-CoA:Cholesterol Acyltransferase Inhibitors
Chapter 4. Company Profiles: Abbott Laboratories; Currently Marketed Drugs for Metabolic Disorders; Drugs in Development; Alizyme; Drugs in Development; Amgen; Drugs in Development; Amylin Pharmaceuticals; Currently Marketed Drugs for Metabolic Disorders; Drugs in Development; AstraZeneca; Currently Marketed Drugs for Metabolic Disorders; Drugs in Development; Bristol-Myers Squibb; Currently Marketed Drugs for Metabolic Disorders; Drugs in Development; Eli Lilly; Currently Marketed Drugs for Metabolic Disorders; Drugs in Development; GlaxoSmithKline; Currently Marketed Drugs for Metabolic Disorders; Drugs in Development; Isis Pharmaceuticals; Drugs in Development; Ligand Pharmaceuticals; Drugs in Development; Merck & Co.; Currently Marketed Drugs for Metabolic Disorders; Drugs in Development; Metabolex; Drugs in Development; Novartis; Currently Marketed Drugs for Metabolic Disorders; Drugs in Development; Novo Nordisk; Currently Marketed Drugs for Metabolic Disorders; Decision Resources, Inc. ii DR Pipeline Reports Pfizer; Currently Marketed Drugs for Metabolic Disorders; Drugs in Development; Roche; Currently Marketed Drugs for Metabolic Disorders; Drugs in Development; Sanofi-Aventis; Currently Marketed Drugs for Metabolic Disorders; Drugs in Development; Schering-Plough; Currently Marketed Drugs for Metabolic Disorders
Chapter 5. Outlook for Metabolic Disease Therapeutics
Bibliography
Decision Resources, Inc. iii DR Pipeline Reports
Tables and Figures
Table 1. Drugs Available in the United States for the Treatment of Obesity
Table 2. NCEP’s ATP III Classification of LDL, Total, and HDL Cholesterol
Table 3. Drugs Available in the United States for the Treatment of Dyslipidemia
Table 4. Definitions of Metabolic Syndrome
Table 5. Drugs Available in the United States for the Treatment of Type 2 Diabetes (Excluding Insulin)
Table 6. Drugs Available in the United States for the Treatment of Dyslipidemia
Table 7. Abbott Laboratories’ Marketed and Investigational Drugs for Metabolic Diseases
Table 8. Amgen’s Marketed and Investigational Drugs for Metabolic Diseases
Table 9. Select Amgen Alliances in the Metabolic Disease Area, 2000-2005
Table 10. Amylin Pharmaceuticals’ Marketed and Investigational Drugs for Metabolic Diseases
Table 11. Select Amylin Pharmaceuticals Alliances in the Metabolic Disease Area, 2000-2005
Table 12. AstraZeneca’s Marketed and Investigational Drugs for Metabolic Diseases
Table 13. Select AstraZeneca Alliances in the Metabolic Disease Area, 2000-2005
Table 14. Bristol-Myers Squibb’s Marketed and Investigational Drugs for Metabolic Diseases
Table 15. Select Bristol-Myers Squibb Alliances in the Metabolic Disease Area, 2000-2005
Table 16. Eli Lilly’s Marketed and Investigational Drugs for Metabolic Diseases
Table 17. Select Eli Lilly Alliances in the Metabolic Disease Area, 2000-2005
Table 18. GlaxoSmithKline’s Marketed and Investigational Drugs for Metabolic Diseases
Table 19. Select GlaxoSmithKline Alliances in the Metabolic Disease Area, 2000-2005
Table 20. Isis Pharmaceuticals’ Marketed and Investigational Drugs for Metabolic Diseases
Table 21. Select Isis Pharmaceuticals Alliances in the Metabolic Disease Area, 2000-2005
Table 22. Ligand Pharmaceuticals’ Marketed and Investigational Drugs for Metabolic Diseases
Table 23. Select Ligand Pharmaceuticals Alliances in the Metabolic Disease Area, 2000-2005: Decision Resources, Inc. iv DR Pipeline Reports
Table 24. Merck’s Marketed and Investigational Drugs for Metabolic Diseases
Table 25. Select Merck Alliances in the Metabolic Disease Area, 2000-2005
Table 26. Metabolex’s Marketed and Investigational Drugs for Metabolic Diseases
Table 27. Select Metabolex Alliances in the Metabolic Disease Area, 2000-2005
Table 28. Novartis’s Marketed and Investigational Drugs for Metabolic Diseases
Table 29. Select Novartis Alliances in the Metabolic Disease Area, 2000-2005
Table 30. Novo Nordisk’s Marketed and Investigational Drugs for Metabolic Diseases
Table 31. Select Novo Nordisk Alliances in the Metabolic Disease Area, 2000-2005
Table 32. Pfizer’s Marketed and Investigational Drugs for Metabolic Diseases
Table 33. Select Pfizer Alliances in the Metabolic Disease Area, 2000-2005
Table 34. Roche’s Marketed and Investigational Drugs for Metabolic Diseases
Table 35. Select Roche Alliances in the Metabolic Disease Area, 2000-2005
Table 36. Sanofi-Aventis’s Marketed and Investigational Drugs for Metabolic Diseases
Table 37. Select Sanofi-Aventis Alliances in the Metabolic Disease Area, 2000-2005
Table 38. Schering-Plough’s Marketed and Investigational Drugs for Metabolic Diseases
Figure 1. Clinical Progression of Type 2 Diabetes
Figure 2. Insulin-Dependent Glucose Transporter Activation and Expression in Skeletal Muscle or Adipocytes
Figure 3. Mechanisms of Action of the Major Pharmacotherapies for Type 2 Diabetes
Figure 4. Worldwide Insulin Sales, 2004
Figure 5. Metabolic Pipelines: Beyond Phase I

Metabolic Diseases Pipeline Analysis:Focus on Dyslipidemia, Diabetes, and Obesity

Share this report

Other tasks

Research Assistance

Related Markets

Cardiovascular Reports

Free Alert Me service